Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PTC THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for PTC THERAPEUTICS, INC.

PTCT

PTC THERAPEUTICS, INC.

About PTC THERAPEUTICS, INC.

PTC Therapeutics is a global biopharmaceutical company focused on discovering and developing medicines for rare genetic and neurological disorders. Its portfolio includes treatments for Duchenne muscular dystrophy, spinal muscular atrophy, and rare metabolic diseases, utilizing gene therapy, antisense oligonucleotides, and small molecules. The company leverages scientific expertise and strategic collaborations to bring innovative therapies to patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PTC THERAPEUTICS, INC.

1
1
PTC THERAPEUTICS, INC. PTC Therapeutics Reports 47% Revenue Growth to $225.6 Million in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
PTC THERAPEUTICS, INC. PTC Therapeutics Reports $586.7M Revenue and Strategic Developments in 10-K Filing

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
PTC THERAPEUTICS, INC. PTC Therapeutics Reports 7% Revenue Growth and Net Income Turnaround in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PTC THERAPEUTICS, INC. PTC Therapeutics Reports Q2 2025 Revenue of $178.9 Million, Net Income Turnaround

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PTC THERAPEUTICS, INC. PTC Therapeutics Reports $1.18 Billion Revenue and $866.6 Million Net Income in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PTC THERAPEUTICS, INC. PTC Therapeutics Reports Mixed Q3 2024 Results, Net Loss Improvement, and Strategic Developments

Via official filing (AI summary) | over 1 year ago | 0 comments